Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study

IF 2.4 4区 医学 Q3 NEUROSCIENCES Clinical Psychopharmacology and Neuroscience Pub Date : 2017-02-01 DOI:10.9758/cpn.2017.15.1.28
S. Jeon, Changsu Han, Y. Ko, S. Yoon, C. Pae, Joonho Choi, Y. Park, Jong-Woo Kim, Ho-Kyoung Yoon, Seung-Duk Ko, A. Patkar, M. Zimmerman
{"title":"Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study","authors":"S. Jeon, Changsu Han, Y. Ko, S. Yoon, C. Pae, Joonho Choi, Y. Park, Jong-Woo Kim, Ho-Kyoung Yoon, Seung-Duk Ko, A. Patkar, M. Zimmerman","doi":"10.9758/cpn.2017.15.1.28","DOIUrl":null,"url":null,"abstract":"Objective This study was aimed at evaluating the diagnostic validity of the Korean version of the Clinically Useful Depression Outcome Scale (CUDOS) with varying follow-up in a typical clinical setting in multiple centers. Methods In total, 891 psychiatric outpatients were enrolled at the time of their intake appointment. Current diagnostic characteristics were examined using the Structured Clinical Interview for DSM-IV (41% major depressive disorder). The CUDOS was measured and compared with three clinician rating scales and four self-report scales. Results The CUDOS showed excellent results for internal consistency (Cronbach’s α, 0.91), test-retest reliability (patients at intake, r=0.81; depressed patients in ongoing treatment, r=0.89), and convergent and discriminant validity (measures of depression, r=0.80; measures of anxiety and somatization, r=0.42). The CUDOS had a high ability to discriminate between different levels of depression severity based on the rating of Clinical Global Impression for depression severity and the diagnostic classification of major depression, minor depression, and non-depression. The ability of the CUDOS to identify patients with major depression was high (area under the receiver operating characteristic curve=0.867). A score of 20 as the optimal cutoff point was suggested when screening for major depression using the CUDOS (sensitivity=89.9%, specificity=69.5%). The CUDOS was sensitive to change after antidepressant treatment: patients with greater improvement showed a greater decrease in CUDOS scores (p<0.001). Conclusion The results of this multi-site outpatient study found that the Korean version of the CUDOS is a very useful measurement for research and for clinical practice.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"15 1","pages":"28 - 34"},"PeriodicalIF":2.4000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.9758/cpn.2017.15.1.28","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Psychopharmacology and Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.9758/cpn.2017.15.1.28","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 14

Abstract

Objective This study was aimed at evaluating the diagnostic validity of the Korean version of the Clinically Useful Depression Outcome Scale (CUDOS) with varying follow-up in a typical clinical setting in multiple centers. Methods In total, 891 psychiatric outpatients were enrolled at the time of their intake appointment. Current diagnostic characteristics were examined using the Structured Clinical Interview for DSM-IV (41% major depressive disorder). The CUDOS was measured and compared with three clinician rating scales and four self-report scales. Results The CUDOS showed excellent results for internal consistency (Cronbach’s α, 0.91), test-retest reliability (patients at intake, r=0.81; depressed patients in ongoing treatment, r=0.89), and convergent and discriminant validity (measures of depression, r=0.80; measures of anxiety and somatization, r=0.42). The CUDOS had a high ability to discriminate between different levels of depression severity based on the rating of Clinical Global Impression for depression severity and the diagnostic classification of major depression, minor depression, and non-depression. The ability of the CUDOS to identify patients with major depression was high (area under the receiver operating characteristic curve=0.867). A score of 20 as the optimal cutoff point was suggested when screening for major depression using the CUDOS (sensitivity=89.9%, specificity=69.5%). The CUDOS was sensitive to change after antidepressant treatment: patients with greater improvement showed a greater decrease in CUDOS scores (p<0.001). Conclusion The results of this multi-site outpatient study found that the Korean version of the CUDOS is a very useful measurement for research and for clinical practice.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用临床有用的抑郁结果量表对残余症状进行基于测量的治疗:韩国验证研究
目的本研究旨在评估韩国版临床有用抑郁结果量表(CUDOS)的诊断有效性,并在多个中心的典型临床环境中进行不同的随访。方法共有891名精神科门诊患者在预约入院时被登记。使用DSM-IV(41%的重度抑郁障碍)的结构化临床访谈来检查当前的诊断特征。测量CUDOS,并将其与三个临床医生评定量表和四个自我报告量表进行比较。结果CUDOS在内部一致性(Cronbachα,0.91)、重测可靠性(摄入时的患者,r=0.81;正在接受治疗的抑郁症患者,r=0.89)、,以及收敛有效性和判别有效性(抑郁测量值,r=0.80;焦虑和躯体化测量值,r=0.42)。CUDOS具有很高的能力,能够根据抑郁症严重程度的临床总体印象评分和重度抑郁症、轻度抑郁症和非抑郁症的诊断分类来区分不同级别的抑郁症严重程度。CUDOS识别重度抑郁症患者的能力很高(受试者操作特征曲线下面积=0.867)。在使用CUDOS筛查重度抑郁症时,建议将20分作为最佳分界点(敏感性=89.9%,特异性=69.5%)。CUDOS对抗抑郁药治疗后的变化很敏感:改善更大的患者表现出结论这项多站点门诊研究的结果发现,韩国版的CUDOS对研究和临床实践是非常有用的测量方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Psychopharmacology and Neuroscience
Clinical Psychopharmacology and Neuroscience NEUROSCIENCESPHARMACOLOGY & PHARMACY-PHARMACOLOGY & PHARMACY
CiteScore
4.70
自引率
12.50%
发文量
81
期刊介绍: Clinical Psychopharmacology and Neuroscience (Clin Psychopharmacol Neurosci) launched in 2003, is the official journal of The Korean College of Neuropsychopharmacology (KCNP), and the associate journal for Asian College of Neuropsychopharmacology (AsCNP). This journal aims to publish evidence-based, scientifically written articles related to clinical and preclinical studies in the field of psychopharmacology and neuroscience. This journal intends to foster and encourage communications between psychiatrist, neuroscientist and all related experts in Asia as well as worldwide. It is published four times a year at the last day of February, May, August, and November.
期刊最新文献
Clinical Reasoning in the Use of Long-acting Aripiprazole in Psychosis in Bilateral Nephrectomy on Hemodialysis. Enhancing the Understanding of Anti-calcitonin Gene-related Peptide Monoclonal Antibodies in Chronic Migraine Prevention. Psychometric Properties of Korean Version of Nonsuicidal Self-injury Inventory: Validation Study of Deliberate Self-harm Inventory. Psychosomatics: Communication of the Central Nervous System through Connection to Tissues, Organs, and Cells. Remembering Chae Won Kim, Pioneer of Psychopharmacology in Korea.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1